These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17188962)

  • 1. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
    Lynch PM
    Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
    Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
    Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
    Wall R; Strickland C; Jamieson B; Lo V
    J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
    [No Abstract]   [Full Text] [Related]  

  • 5. VICTOR spoiled?
    Goldberg RM; Bertagnolli MM
    J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
    [No Abstract]   [Full Text] [Related]  

  • 6. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
    N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rofecoxib in mild cognitive impairment.
    Ownby RL
    Curr Psychiatry Rep; 2006 Feb; 8(1):9-10. PubMed ID: 16513035
    [No Abstract]   [Full Text] [Related]  

  • 11. COX-2 selective inhibitors and heart health.
    Simon LS; White WB
    Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 inhibitors: cancer prevention or cardiovascular risk?
    Senior K
    Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
    [No Abstract]   [Full Text] [Related]  

  • 13. The COX-2 story: is any drug completely "safe?".
    DuBois RN
    Gastroenterology; 2006 Jan; 130(1):6. PubMed ID: 16401461
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY
    Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
    Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
    Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
    [No Abstract]   [Full Text] [Related]  

  • 16. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 17. COX-2 inhibitors and heart.
    Manoria P; Manoria PC
    Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
    [No Abstract]   [Full Text] [Related]  

  • 18. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
    Lévesque LE; Brophy JM; Zhang B
    CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention with special reference to inherited colorectal cancer.
    Lynch PM
    Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.